Boston Scientific Co. (NYSE:BSX) Stock Position Raised by MinichMacGregor Wealth Management LLC

MinichMacGregor Wealth Management LLC grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,689 shares of the medical equipment provider’s stock after buying an additional 130 shares during the quarter. MinichMacGregor Wealth Management LLC’s holdings in Boston Scientific were worth $508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in BSX. Raleigh Capital Management Inc. lifted its stake in Boston Scientific by 8.4% in the fourth quarter. Raleigh Capital Management Inc. now owns 5,809 shares of the medical equipment provider’s stock valued at $519,000 after acquiring an additional 449 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Boston Scientific by 4.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 207,162 shares of the medical equipment provider’s stock valued at $18,504,000 after purchasing an additional 8,522 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Boston Scientific by 620.7% in the 4th quarter. SG Americas Securities LLC now owns 228,695 shares of the medical equipment provider’s stock valued at $20,427,000 after purchasing an additional 196,961 shares during the last quarter. Daymark Wealth Partners LLC boosted its holdings in Boston Scientific by 18.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 3,981 shares of the medical equipment provider’s stock worth $356,000 after purchasing an additional 627 shares in the last quarter. Finally, Investment Advisory Group LLC acquired a new position in Boston Scientific during the fourth quarter worth $205,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 over the last three months. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BSX. Citigroup increased their price objective on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. TD Cowen upped their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. Finally, Truist Financial increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.26.

Boston Scientific Trading Down 0.6 %

BSX opened at $100.29 on Thursday. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $101.65. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $91.68 and a two-hundred day moving average price of $85.04. The stock has a market capitalization of $147.81 billion, a PE ratio of 82.88, a PEG ratio of 2.64 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the company earned $0.50 EPS. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, equities analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.